NASDAQ: RMTI · Life Sciences · 3 alerts · CIK 1041024
Share price
$6.76Close, Nov 16
Market cap
$27.2M
Shares outstanding
4.03MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rockwell Medical, Inc. filings on SEC EDGAR ↗
Rockwell Medical reported net sales of $19.1 million for Q3 2026, a 20% increase over the prior year, though net loss widened to $2.3 million. The company maintained a cash and investment position of $22.5 million while managing a total accumulated deficit of $408.1 million.
Rockwell Medical reported third quarter 2026 net sales of $19.1 million, a 20% increase year-over-year, driven by higher volumes from existing and new customers. The company highlighted its pending transformational acquisition of Vantive's hemodialysis business, which is projected to generate annual revenue between $400 million and $450 million.
Term
Q3 2026
“We have maintained solid upward momentum across our business, driven by robust market demand and disciplined execution. Our third quarter 2026 net sales grew 20% year-over-year, reflecting strong customer adoption and market validation of our products.”
Mark Strobeck, Ph.D., President and Chief Executive Officer
Rockwell Medical Signs $125M M&A Deal with Vantive Limited
Rockwell Medical has entered into a definitive agreement to acquire Vantive Limited's global in-center hemodialysis business for a base purchase price of $125 million. The acquisition includes manufacturing facilities in Italy, operations in 35 jurisdictions, and a product portfolio spanning concentrates, machines, and water treatment systems. The deal is expected to transform Rockwell into a global provider with projected annual revenues between $400 million and $450 million.
Value
$125M
Counterparty
Vantive Limited
“Acquiring Vantive’s hemodialysis assets and associated operations represents a transformative step in Rockwell Medical’s evolution and directly advances the strategy we have been executing over the past several years.”
Mark Strobeck, Ph.D., President and Chief Executive Officer at Rockwell Medical